Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GPX 002

Next Previous
Search
Drug Profile

GPX 002

Alternative Names: Diabetes gene therapy - Genprex; GPX-002

Latest Information Update: 05 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Pittsburgh
  • Developer Genprex
  • Class Antihyperglycaemics; Gene therapies
  • Mechanism of Action Gene transference; Maf transcription factor replacements; Pancreatic and duodenal homeobox 1 protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 05 Apr 2024 Preclinical development is ongoing in USA (Genprex pipeline, April 2024)
  • 03 Apr 2024 Pharmacodynamics data from a preclinical study in Type 1 diabetes mellitus released by Genprex
  • 01 Apr 2024 Preclinical trials in Type 2 diabetes mellitus in USA (Parenteral) (Genprex pipeline, April 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top